explore
Previous article:
New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article: Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
Next article: Despite FDA approval for Lyfgenia, Bluebird faces stiff competition
hotspot
focus
-
STAT Summit: How researchers deal with rejection
2025-10-01 00:49 -
The woman behind the Dana Farber
2025-10-01 00:30 -
STAT Summit: Ending the crisis of Black deaths in the U.S.
2025-10-01 00:08 -
AI models in health care face new federal disclosure requirements
2025-09-30 23:39 -
Pharma patents targeted by Biden in move to slash drug prices
2025-09-30 22:41 -
Why sickle cell disease is getting the first CRISPR treatment
2025-09-30 22:40